Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
暂无分享,去创建一个
N. Kröger | M. Robin | I. Yakoub-Agha | J. Passweg | D. Mclornan | M. Ladetto | A. Radujkovic | K. Mauff | F. Ciceri | E. Angelucci | U. Platzbecker | A. Rambaldi | Y. Chalandon | M. Stelljes | J. Mayer | J. Hernández-Boluda | P. Hayden | L. Koster | T. Czerw | X. Poiré | M. Nabergoj | S. L. Petersen | S. Robinson | Fridrich Stölzel | L. de Wreede | J. Hernández‐Boluda
[1] N. Kröger,et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT , 2019, Blood Cancer Journal.
[2] A. Migliaccio. Faculty Opinions recommendation of MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[3] M. Labopin,et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation , 2019, British journal of haematology.
[4] N. Kröger,et al. Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] M. Robin,et al. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 , 2019, Haematologica.
[6] A. Tefferi. Primary myelofibrosis. , 2008, Cancer treatment and research.
[7] M. Griesshammer,et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet , 2018, Leukemia.
[8] P. Guglielmelli,et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis , 2018, Leukemia.
[9] A. Tefferi,et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients , 2018, Leukemia.
[10] M. Cazzola,et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Rowe,et al. Allogeneic stem-cell transplantation for myelofibrosis , 2017, Current opinion in hematology.
[12] M. Heuser,et al. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] S. Chevret,et al. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] U. Pein,et al. Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation , 2016 .
[15] R. Mesa,et al. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis , 2016, Haematologica.
[16] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[17] N. Kröger,et al. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT , 2015, British journal of haematology.
[18] N. Kröger,et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.
[19] R. Latagliata,et al. Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. , 2015, Leukemia research.
[20] N. Kröger,et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Kröger,et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting , 2012, British journal of haematology.
[22] M. Bernard,et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.
[23] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Tefferi,et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.
[25] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[26] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[27] M. Cazzola,et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.